<div id="readability-page-1">Cellectis A/S on Wednesday published an article in Nature Communications establishing circular single-stranded DNA (CssDNA) as a highly efficient non-viral DNA donor template for gene insertion in hematopoietic stem and progenitor cells (HSPCs). HSPCs are rare, self-renewing cells in the bone marrow that mature into all blood cells, including red blood cells, white blood cells, and platelets. Gene editing of HSPCs offers the potential for long-term therapeutic benefit. While viral vectors such as AAV6 are commonly used for gene insertion, they raise safety and efficacy concerns. Over the past decade, non-viral DNA templates delivery has emerged as promising alternatives and have been used with nucleases to target short single-stranded linear DNA corrective template in HSPCs. Although non-viral approaches were initially limited to making only small corrections within defective genes, Cellectis ( CLLS ) harnessed its TALEN technology and CssDNA donor templates to develop a gene insertion process. This process enables precise and efficient integration of large genetic sequences within therapeutically relevant subpopulations of HSPCs, significantly expanding the potential of non-viral gene therapy. The results show that: <ul> <li>CssDNA achieved 3-5 times higher knock-in efficiency than linear single-stranded DNA (LssDNA), with values surpassing 40%.</li> <li>CssDNA can be used to insert genes at multiple loci in HSPCs and applies to other cell types of therapeutic interest, including primary T cells.</li> <li>Comparative studies also showed that CssDNA-edited HSPCs demonstrate a higher propensity to engraft and maintain gene edits in a murine model compared to AAV6-edited HSPCs.</li> </ul> “These results establish the CssDNA process as an efficient non-viral gene insertion strategy, and mark a pivotal advance towards the development of next-generation cell and gene therapies,” said Julien Valton, Vice President of Gene Therapy of Cellectis ( CLLS ). As of September 30, 2025, Cellectis ( CLLS ) had $225 million in consolidated cash, cash equivalents, restricted cash, and fixed-term deposits. The company believes its cash, cash equivalents, and fixed-term deposits will be sufficient to fund its operations into the second half of 2027. Price Action: CLLS stock is up 8.27% at $4.45 at the last check on Thursday. Read Next: <ul> <li>Broadcom Expands NEC Partnership To Help Businesses Modernize Cloud Setups</li> </ul> Photo via Shutterstock</div>

CLLS

Cellectis A/S 宣布在基因治疗方面取得突破，使用环状单链 DNA（CssDNA）实现了在造血干细胞和祖细胞（HSPCs）中高效的基因插入。这一进展利用了 TALEN 技术，增强了非病毒基因治疗的潜力。CssDNA 在不同细胞类型中显示出更高的效率和适用性，标志着细胞和基因治疗的重要一步。因此，Cellectis 的股票上涨了 8.27%，达到 4.45 美元。该公司拥有 2.25 亿美元的现金储备，足以支持其运营直到 2027 年下半年

为什么 Cellectis 的股票今天上涨